A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Bradley Bloom, MD, FACR, FAAP
Vertex Pharmaceuticals Incorporated
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Vertex Investigational Site
Hillerød, Denmark
- Vertex Investigational Site
Hjørring, Denmark
- Vertex Investigational Site
Tallinn, Estonia
- Vertex Investigational Site
Vilnius, Lithuania
- Vertex Investigational Site
Heerlen, Netherlands
- Vertex Investigational Site
Utrecht, Netherlands
- Vertex Investigational Site
Johannesburg, South Africa
- Vertex Investigational Site
Pretoria, South Africa
- Vertex Investigational Site
Stellenbosch, South Africa
- Vertex Investigational Site
Stanford, California, United States
- Vertex Investigational Site
Upland, California, United States
- Vertex Investigational Site
Fort Lauderdale, Florida, United States
- Vertex Investigational Site
Venice, Florida, United States
- Vertex Investigational Site
West Palm Beach, Florida, United States
- Vertex Investigational Site
Canton, Georgia, United States
- Vertex Investigational Site
Decatur, Georgia, United States
- Vertex Investigational Site
Kansas City, Kansas, United States
- Vertex Investigational Site
Elizabethtown, Kentucky, United States
- Vertex Investigational Site
Frederick, Maryland, United States
- Vertex Investigational Site
Lincoln, Nebraska, United States
- Vertex Investigational Site
Rochester, New York, United States
- Vertex Investigational Site
Greenboro, North Carolina, United States
- Vertex Investigational Site
Duncansville, Pennsylvania, United States
- Vertex Investigational Site
Charleston, South Carolina, United States
- Vertex Investigational Site
Memphis, Tennessee, United States
- Vertex Investigational Site
Katy, Texas, United States
- Vertex Investigational Site
San Antonio, Texas, United States
- Vertex Investigational Site
Webster, Texas, United States
- Vertex Investigational Site
Seattle, Washington, United States
- Vertex Investigational Site
Spokane, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2013
- Primary completion
- 31 Jan 2014
- Completion
- 28 Feb 2014
- Last update posted
- 19 May 2015
- Registered enrollment
- 43
- Registry id
- NCT01754935
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.